CA3246487A1 - MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS - Google Patents
MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORSInfo
- Publication number
- CA3246487A1 CA3246487A1 CA3246487A CA3246487A CA3246487A1 CA 3246487 A1 CA3246487 A1 CA 3246487A1 CA 3246487 A CA3246487 A CA 3246487A CA 3246487 A CA3246487 A CA 3246487A CA 3246487 A1 CA3246487 A1 CA 3246487A1
- Authority
- CA
- Canada
- Prior art keywords
- nrerf
- alkyl
- nres
- 2nrerf
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296705P | 2022-01-05 | 2022-01-05 | |
| US63/296,705 | 2022-01-05 | ||
| US202263435654P | 2022-12-28 | 2022-12-28 | |
| US63/435,654 | 2022-12-28 | ||
| PCT/US2023/060039 WO2023133375A1 (en) | 2022-01-05 | 2023-01-03 | Macrocyclic compounds and use as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246487A1 true CA3246487A1 (en) | 2023-07-13 |
Family
ID=87074235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246487A Pending CA3246487A1 (en) | 2022-01-05 | 2023-01-03 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250074920A1 (https=) |
| EP (1) | EP4460498A4 (https=) |
| JP (1) | JP2025503592A (https=) |
| KR (1) | KR20240131416A (https=) |
| AU (1) | AU2023204770A1 (https=) |
| CA (1) | CA3246487A1 (https=) |
| IL (1) | IL314070A (https=) |
| MX (1) | MX2024008413A (https=) |
| TW (1) | TW202334168A (https=) |
| WO (1) | WO2023133375A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024266587A1 (en) * | 2023-05-02 | 2025-09-11 | Blossomhill Therapeutics, Inc. | Egfr inhibitors for treating disease |
| WO2025212729A1 (en) * | 2024-04-03 | 2025-10-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03376B (me) * | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| US20160031888A1 (en) * | 2013-03-13 | 2016-02-04 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| TWI707852B (zh) * | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| EP4178958A4 (en) * | 2020-07-10 | 2024-12-11 | Blossomhill Therapeutics, Inc. | MACROCYCLES AND THEIR USE |
-
2023
- 2023-01-03 AU AU2023204770A patent/AU2023204770A1/en active Pending
- 2023-01-03 WO PCT/US2023/060039 patent/WO2023133375A1/en not_active Ceased
- 2023-01-03 MX MX2024008413A patent/MX2024008413A/es unknown
- 2023-01-03 KR KR1020247025807A patent/KR20240131416A/ko active Pending
- 2023-01-03 CA CA3246487A patent/CA3246487A1/en active Pending
- 2023-01-03 JP JP2024540747A patent/JP2025503592A/ja active Pending
- 2023-01-03 EP EP23737695.9A patent/EP4460498A4/en active Pending
- 2023-01-03 US US18/725,951 patent/US20250074920A1/en active Pending
- 2023-01-03 IL IL314070A patent/IL314070A/en unknown
- 2023-01-05 TW TW112100378A patent/TW202334168A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024008413A (es) | 2024-09-17 |
| US20250074920A1 (en) | 2025-03-06 |
| TW202334168A (zh) | 2023-09-01 |
| EP4460498A1 (en) | 2024-11-13 |
| EP4460498A4 (en) | 2026-03-25 |
| JP2025503592A (ja) | 2025-02-04 |
| AU2023204770A1 (en) | 2024-07-18 |
| KR20240131416A (ko) | 2024-08-30 |
| WO2023133375A1 (en) | 2023-07-13 |
| IL314070A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404281B2 (en) | Diaryl macrocycles as modulators of protein kinases | |
| AU2021401741A1 (en) | Macrocycles and their use | |
| CA3246487A1 (en) | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | |
| US20240374606A1 (en) | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer | |
| TW202413377A (zh) | 吲唑巨環化合物及其用途 | |
| IL324276A (en) | Egfr inhibitors for treating disease | |
| WO2025212729A1 (en) | Macrocyclic compounds and their use | |
| WO2025010294A2 (en) | Macrocyclic compounds and use as tyk2 inhibitors | |
| WO2025199438A1 (en) | 7-azaindazole macrocycles and their use | |
| HK40109104A (en) | Diaryl macrocycles as modulators of protein kinases | |
| WO2026064346A1 (en) | Tetracyclic-macrocycles and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240703 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241209 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250207 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250207 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260416 |